In conclusion, we developed and interpreted two optimal predictive models to identify EGFR mutation status and subtypes in patients with lung adenocarcinoma based on cross-combination method and XAI technology, and further constructed a prognostic model to predict their clinical outcome. The gene discussed is EGFR; the disease is lung adenocarcinoma.